Muscle Spasticity Pipeline Insight 2025: Advancing Neuromuscular Therapies for Improved Mobility and Quality of Life | DelveInsight

DelveInsight's "Muscle Spasticity - Pipeline Insight, 2025" report offers a comprehensive evaluation of the drug development landscape targeting muscle spasticity across conditions such as multiple sclerosis (MS), cerebral palsy (CP), stroke, traumatic brain injury (TBI), and spinal cord injury. The report tracks over 15 pipeline therapies in various stages of development, focusing on novel muscle relaxants, neurotoxins, and neuromodulators.

Spasticity, characterized by involuntary muscle stiffness and spasms, remains a major challenge in neurological rehabilitation. While standard treatments such as baclofen, tizanidine, and botulinum toxins offer symptomatic relief, their limited duration of action and side effect profiles have prompted the need for more targeted and long-lasting therapies.

Emerging candidates, including selective GABA-B receptor modulators, botulinum toxin variants, and intrathecal agents, are being developed to provide enhanced efficacy, fewer systemic side effects, and improved delivery. Companies like Ipsen, Revance Therapeutics, Medytox, and Merz are leading innovation in this space with therapies such as Daxxify (RT002), Nabota, and novel botulinum toxin analogs.

DelveInsight's report provides a detailed pipeline analysis by mechanism of action, stage of development, route of administration, and target indications. It also identifies key trends in clinical trial design, biomarker utilization, and regulatory strategies that are shaping the future of spasticity treatment.

As the burden of neuromuscular disorders continues to grow, pipeline therapies for muscle spasticity hold promise in restoring motor function, improving independence, and enhancing quality of life for affected patients.

Interested in learning more about the current treatment landscape and the key drivers shaping the muscle spasticity pipeline? Click here: https://www.delveinsight.com/report-store/muscle-spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Muscle Spasticity Pipeline Report
• DelveInsight's muscle spasticity pipeline analysis depicts a strong space with 15+ active players working to develop 15+ pipeline drugs for muscle spasticity treatment.
• The leading muscle spasticity companies include Saol Therapeutics, Daewoong Pharmaceutical, AbbVie, Supernus Pharmaceuticals, Revance Therapeutics, Ipsen, Abide Therapeutics, Motor Pharma, BetterLife Pharma, RVL Pharmaceuticals, and others are evaluating their lead assets to improve the muscle spasticity treatment landscape.
• Key muscle spasticity pipeline therapies in various stages of development include SIL 1002, Prabotulinumtoxin A, Onabotulinum toxin A, Botulinum toxin B, Daxibotulinumtoxin A, Botulinum toxin A, Botulinum toxin A longer acting, Lu AG06466, MPH 220, BETR 002, Arbaclofen extended release, and others.
• LYVISPAH (baclofen oral granules) was approved by the FDA on December 9, 2021, for treating spasticity in patients aged 12 and older with multiple sclerosis, offering an easy-to-administer, dissolvable formulation for relieving spasms and muscle pain
• A Phase II trial in China is testing the combined efficacy of transcranial magnetic stimulation (TMS) and extracorporeal shockwave therapy (ESWT) for post-stroke spasticity, with primary outcomes using the Modified Ashworth scale. Enrollment began in January 2024.

Request a sample and discover the recent breakthroughs happening in the muscle spasticity pipeline landscape at https://www.delveinsight.com/report-store/muscle-spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Muscle Spasticity Overview
Muscle spasticity is a neurological condition characterized by involuntary muscle stiffness, tightness, or spasms, typically caused by damage to the central nervous system. It is commonly associated with disorders such as multiple sclerosis, cerebral palsy, stroke, spinal cord injury, and traumatic brain injury. This disruption leads to an imbalance in nerve signals, resulting in continuous muscle contractions, increased muscle tone, and reduced motor control, often affecting mobility, posture, and quality of life.

Current management strategies include oral muscle relaxants like baclofen and tizanidine, botulinum toxin injections, intrathecal drug delivery, and physical therapy. However, treatment effectiveness can vary, and many patients experience side effects or limited relief. As a result, there is a growing focus on developing longer-acting, targeted therapies and neuromodulators to better manage spasticity and improve patient outcomes.

Find out more about muscle spasticity medication at https://www.delveinsight.com/report-store/muscle-spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Muscle Spasticity Treatment Analysis: Drug Profile
Arbaclofen ER: Janssen Pharmaceutical
Arbaclofen ER is an extended-release formulation of the R-isomer of baclofen, designed using the proprietary Osmodex® drug delivery system. It is currently being developed for the treatment of spasticity associated with multiple sclerosis.

Lu AG06466: Abide Therapeutics (now Lundbeck A/S)
Lu AG06466 (formerly ABX-1431) is an oral small molecule under development for the treatment of neuropathic pain, irritable bowel syndrome-related pain, multiple sclerosis-related spasticity, fibromyalgia, and epilepsy.

Learn more about the novel and emerging muscle spasticity pipeline therapies at https://www.delveinsight.com/report-store/muscle-spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Muscle Spasticity Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous

By Molecule Type
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Muscle Spasticity Pipeline Report
• Coverage: Global
• Key Muscle Spasticity Companies: Saol Therapeutics, Daewoong Pharmaceutical, AbbVie, Supernus Pharmaceuticals, Revance Therapeutics, Ipsen, Abide Therapeutics, Motor Pharma, BetterLife Pharma, RVL Pharmaceuticals, and others.
• Key Muscle Spasticity Pipeline Therapies: SIL 1002, Prabotulinumtoxin A, Onabotulinum toxin A, Botulinum toxin B, Daxibotulinumtoxin A, Botulinum toxin A, Botulinum toxin A longer acting, Lu AG06466, MPH 220, BETR 002, Arbaclofen extended release, and others.

To dive deep into rich insights for drugs used for muscle spasticity treatment, visit: https://www.delveinsight.com/report-store/muscle-spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Muscle Spasticity Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Muscle Spasticity Pipeline Therapeutics
6. Muscle Spasticity Pipeline: Late-Stage Products (Phase III)
7. Muscle Spasticity Pipeline: Mid-Stage Products (Phase II)
8. Muscle Spasticity Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.